Anavex生命科学 AVXL 深 沪
等待开盘 11-25 09:30:00 美东时间
3.16
-0.100
-3.07%
华盛通- 最 高3.2915
- 今 开3.23
- 成交量 72.39万股
- 最 低 3.125
- 昨 收 3.26
- 总市值 2.71亿
- 52周最高 14.4405
- 市盈率 静 --
- 换手率 0.84%
- 52周最低 2.86
- 委 比 15.51%
- 总股本 8589.38万
- 历史最高 31.50
- 量 比 0.57
- 振 幅 5.11%
- 历史最低 0.60
- 每 手 1
- 风险率 1.47%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多A Preview Of Anavex Life Sciences's Earnings
Anavex Life Sciences (NASDAQ:AVXL) is preparing to release its quarterly earnin...
48分钟前
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference
Anavex Life Sciences Corp. will present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026, in San Francisco. Christopher U Missling, PhD, President & CEO, will discuss the Company’s progress in developing innovative treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Anavex’s lead drug candidate, ANAVEX®2-73, has completed Phase 2a, Phase 2b/3 trials for Alzheimer's disease, Phase 2 proof-o...
11-19 12:30
Red Cat Posts Downbeat Q3 Results, Joins StubHub, WhiteFiber And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
11-14 21:17
Anavex tumbles as Alzheimer’s therapy faces EU rejection
Anavex Life Sciences (AVXL) lost ~47% in the premarket on Friday after a group of experts appointed by the EU drug regulator, the European Medicines Agency (EMA), turned down its Alzheimer’s therapy, ...
11-14 21:06
Anavex Faces CHMP Setback for Alzheimer’s Drug
Anavex Life Sciences ( ($AVXL) ) has issued an update. On November 14, 2025, An...
11-14 20:58
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
D. Boral Capital Maintains Buy on Anavex Life Sciences, Maintains $46 Price Target
D. Boral Capital analyst Jason Kolbert maintains Anavex Life Sciences (NASDAQ:AVXL) with a Buy and maintains $46 price target.
10-29 20:43
Anavex Life Sciences' Alzheimer's Drug Candidate Shows Continued Long-Term Benefit Versus Control Group
Anavex reports sustained cognitive benefits from oral blarcamesine, showing slower Alzheimer's progression and long-term efficacy over 144 weeks.
10-29 19:31
Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) Control Group
Anavex Life Sciences announced positive findings for oral blarcamesine in treating early Alzheimer’s disease, showing a significant cognitive benefit compared to the ADNI control group. At Week 144, the ADAS-Cog13 score difference was −12.78 (P < 0.0001), with 77.4 weeks of disease progression delay. Blarcamesine restores autophagy, addressing early molecular changes, and demonstrated a favorable safety profile.
10-29 11:30
